E
Aytu Biopharma, Inc.
AYTU
$1.26
$0.00090.07%
E
Sell
10/31/2024Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 10/31/2024 due to a decline in the total return index and volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 10/31/2024 due to a decline in the total return index and volatility index.
D
Sell
10/15/2024Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 10/15/2024 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 10/15/2024 due to an increase in the volatility index.
E
Sell
9/27/2024Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 9/27/2024 due to a decline in the volatility index, solvency index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 9/27/2024 due to a decline in the volatility index, solvency index and total return index.
D
Sell
9/24/2024Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 9/24/2024 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 9/24/2024 due to an increase in the volatility index.
E
Sell
9/5/2024Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 9/5/2024 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 9/5/2024 due to a decline in the volatility index and total return index.
D
Sell
8/19/2024Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 8/19/2024 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 8/19/2024 due to an increase in the volatility index.
E
Sell
7/24/2024Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 7/24/2024 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 7/24/2024 due to a decline in the volatility index.
D
Sell
7/9/2024Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 7/9/2024 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 7/9/2024 due to an increase in the volatility index.
E
Sell
6/20/2024Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index and total return index.
D
Sell
6/4/2024Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index, total return index and solvency index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index, total return index and solvency index.
E
Sell
5/17/2024Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index.
D
Sell
5/2/2024Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 5/2/2024 due to an increase in the total return index and volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 5/2/2024 due to an increase in the total return index and volatility index.
E
Sell
4/17/2024Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
D
Sell
4/1/2024Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 4/1/2024 due to a significant increase in the growth index, solvency index and total return index. EBIT increased 257.18% from -$1.5M to $2.36M, earnings per share increased from -$1.4812 to -$0.0399, and operating cash flow increased 36.02% from -$211 to -$135.
Aytu Biopharma, Inc. (AYTU) was upgraded to D- from E+ on 4/1/2024 due to a significant increase in the growth index, solvency index and total return index. EBIT increased 257.18% from -$1.5M to $2.36M, earnings per share increased from -$1.4812 to -$0.0399, and operating cash flow increased 36.02% from -$211 to -$135.
E
Sell
10/6/2023Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 10/6/2023 due to an increase in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 10/6/2023 due to an increase in the volatility index and total return index.
E
Sell
9/21/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 9/21/2023 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 9/21/2023 due to a decline in the volatility index.
E
Sell
9/5/2023Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 9/5/2023 due to an increase in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 9/5/2023 due to an increase in the volatility index and total return index.
E
Sell
8/18/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 8/18/2023 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 8/18/2023 due to a decline in the volatility index.
E
Sell
7/31/2023Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 7/31/2023 due to an increase in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 7/31/2023 due to an increase in the volatility index and total return index.
E
Sell
7/14/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 7/14/2023 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 7/14/2023 due to a decline in the volatility index.
E
Sell
6/23/2023Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 6/23/2023 due to an increase in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 6/23/2023 due to an increase in the volatility index and total return index.
E
Sell
6/7/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 6/7/2023 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 6/7/2023 due to a decline in the volatility index.
E
Sell
5/22/2023Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 5/22/2023 due to a noticeable increase in the growth index, solvency index and volatility index. Earnings per share increased from -$2.1519 to -$1.932.
Aytu Biopharma, Inc. (AYTU) was upgraded to E+ from E on 5/22/2023 due to a noticeable increase in the growth index, solvency index and volatility index. Earnings per share increased from -$2.1519 to -$1.932.
E
Sell
5/5/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 5/5/2023 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E from E+ on 5/5/2023 due to a decline in the volatility index and total return index.
E
Sell
3/9/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 3/9/2023 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 3/9/2023 due to a decline in the volatility index and total return index.
D
Sell
2/22/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 2/22/2023 due to a noticeable decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.2776 to -$2.1519, EBIT declined 153.66% from -$1.65M to -$4.19M, and debt to equity increased from 0.44 to 0.51.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 2/22/2023 due to a noticeable decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.2776 to -$2.1519, EBIT declined 153.66% from -$1.65M to -$4.19M, and debt to equity increased from 0.44 to 0.51.
D
Sell
2/9/2023Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
D
Sell
2/3/2023Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 2/3/2023 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 2/3/2023 due to a decline in the volatility index and total return index.
D
Sell
1/19/2023Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 1/19/2023 due to an increase in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 1/19/2023 due to an increase in the volatility index and total return index.
D
Sell
12/29/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 12/29/2022 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 12/29/2022 due to a decline in the volatility index and total return index.
D
Sell
12/12/2022Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 12/12/2022 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 12/12/2022 due to an increase in the volatility index.
D
Sell
11/25/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 11/25/2022 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 28.94% from -$7.1M to -$9.15M.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 11/25/2022 due to a noticeable decline in the growth index and volatility index. Operating cash flow declined 28.94% from -$7.1M to -$9.15M.
D
Sell
9/30/2022Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 9/30/2022 due to a substantial increase in the growth index and total return index. Earnings per share increased from -$1.7876 to -$0.4923, EBIT increased 24.9% from -$9.46M to -$7.1M, and operating cash flow increased 22.16% from -$9.12M to -$7.1M.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 9/30/2022 due to a substantial increase in the growth index and total return index. Earnings per share increased from -$1.7876 to -$0.4923, EBIT increased 24.9% from -$9.46M to -$7.1M, and operating cash flow increased 22.16% from -$9.12M to -$7.1M.
D
Sell
5/19/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 5/19/2022 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from -$0.4372 to -$1.7876, debt to equity increased from 0.23 to 0.31, and operating cash flow declined 3.32% from -$8.82M to -$9.12M.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 5/19/2022 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from -$0.4372 to -$1.7876, debt to equity increased from 0.23 to 0.31, and operating cash flow declined 3.32% from -$8.82M to -$9.12M.
D
Sell
5/17/2022Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 04/21/2022.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 04/20/2022.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D- on 04/20/2022.
D
Sell
4/18/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 4/18/2022 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 4/18/2022 due to a decline in the volatility index and total return index.
D
Sell
3/30/2022Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 3/30/2022 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 3/30/2022 due to an increase in the volatility index.
D
Sell
3/15/2022Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 3/15/2022 due to a decline in the volatility index and total return index.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 3/15/2022 due to a decline in the volatility index and total return index.
D
Sell
2/17/2022Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 2/17/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$1.088 to -$0.4372, and total revenue increased 5.61% from $21.9M to $23.13M.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 2/17/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$1.088 to -$0.4372, and total revenue increased 5.61% from $21.9M to $23.13M.
D
Sell
11/17/2021Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 11/17/2021 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.8077 to -$1.088, the quick ratio declined from 0.71 to 0.63, and total revenue declined 6.75% from $23.48M to $21.9M.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 11/17/2021 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.8077 to -$1.088, the quick ratio declined from 0.71 to 0.63, and total revenue declined 6.75% from $23.48M to $21.9M.
D
Sell
11/9/2021Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
D
Sell
11/4/2021Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 11/4/2021 due to an increase in the volatility index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 11/4/2021 due to an increase in the volatility index.
D
Sell
10/13/2021Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 10/13/2021 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.89 to 0.71, and debt to equity increased from 0.16 to 0.19.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 10/13/2021 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.89 to 0.71, and debt to equity increased from 0.16 to 0.19.
D
Sell
5/18/2021Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 5/18/2021 due to a noticeable increase in the growth index and total return index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 5/18/2021 due to a noticeable increase in the growth index and total return index.
D
Sell
5/14/2021Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 5/14/2021 due to a decline in the volatility index.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 5/14/2021 due to a decline in the volatility index.
D
Sell
4/14/2021Upgraded
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 4/14/2021 due to an increase in the volatility index and valuation index.
Aytu Biopharma, Inc. (AYTU) was upgraded to D from D- on 4/14/2021 due to an increase in the volatility index and valuation index.
D
Sell
3/29/2021Downgrade
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 3/29/2021 due to a decline in the volatility index, total return index and valuation index.
Aytu Biopharma, Inc. (AYTU) was downgraded to D- from D on 3/29/2021 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/12/2021Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 3/12/2021 due to an increase in the volatility index and valuation index.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 3/12/2021 due to an increase in the volatility index and valuation index.
D
Sell
2/12/2021Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 2/12/2021 due to a decline in the total return index, volatility index and valuation index.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 2/12/2021 due to a decline in the total return index, volatility index and valuation index.
D
Sell
9/29/2020Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 9/29/2020 due to an increase in the volatility index.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 9/29/2020 due to an increase in the volatility index.
D
Sell
9/14/2020Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 9/14/2020 due to a decline in the volatility index and total return index.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 9/14/2020 due to a decline in the volatility index and total return index.
D
Sell
8/27/2020Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 8/27/2020 due to an increase in the volatility index.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 8/27/2020 due to an increase in the volatility index.
D
Sell
8/12/2020Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 8/12/2020 due to a decline in the volatility index and total return index.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 8/12/2020 due to a decline in the volatility index and total return index.
D
Sell
7/27/2020Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 7/27/2020 due to an increase in the volatility index and total return index.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 7/27/2020 due to an increase in the volatility index and total return index.
D
Sell
7/10/2020Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 7/10/2020 due to a decline in the volatility index.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 7/10/2020 due to a decline in the volatility index.
D
Sell
6/8/2020Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 6/8/2020 due to an increase in the volatility index and total return index.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 6/8/2020 due to an increase in the volatility index and total return index.
D
Sell
5/20/2020Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 5/20/2020 due to a noticeable decline in the growth index, efficiency index and volatility index. Net income declined 2,389.4% from -$214.2 to -$5.33M, earnings per share declined from -$0.0122 to -$0.1512, and operating cash flow declined 88.91% from -$6.1M to -$11.52M.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 5/20/2020 due to a noticeable decline in the growth index, efficiency index and volatility index. Net income declined 2,389.4% from -$214.2 to -$5.33M, earnings per share declined from -$0.0122 to -$0.1512, and operating cash flow declined 88.91% from -$6.1M to -$11.52M.
D
Sell
4/1/2020Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 4/1/2020 due to an increase in the volatility index and total return index.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 4/1/2020 due to an increase in the volatility index and total return index.
D
Sell
3/17/2020Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 3/17/2020 due to a decline in the growth index, volatility index and efficiency index. Operating cash flow declined 104.14% from -$2.99M to -$6.1M, and EBIT declined 4.89% from -$4.74M to -$4.97M.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 3/17/2020 due to a decline in the growth index, volatility index and efficiency index. Operating cash flow declined 104.14% from -$2.99M to -$6.1M, and EBIT declined 4.89% from -$4.74M to -$4.97M.
D
Sell
9/30/2019Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 9/30/2019 due to an increase in the efficiency index and volatility index.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 9/30/2019 due to an increase in the efficiency index and volatility index.
D
Sell
5/15/2019Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 5/15/2019 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 0.25 to 0.32, total capital declined 15.09% from $24.93M to $21.17M, and the quick ratio declined from 4.14 to 3.56.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 5/15/2019 due to a significant decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 0.25 to 0.32, total capital declined 15.09% from $24.93M to $21.17M, and the quick ratio declined from 4.14 to 3.56.
D
Sell
2/15/2019Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 2/15/2019 due to a significant increase in the efficiency index, solvency index and volatility index. The quick ratio increased from 1.32 to 4.14, and total capital increased 146.14% from $10.13M to $24.93M.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 2/15/2019 due to a significant increase in the efficiency index, solvency index and volatility index. The quick ratio increased from 1.32 to 4.14, and total capital increased 146.14% from $10.13M to $24.93M.
D
Sell
11/8/2018Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 11/8/2018 due to a major decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.3051 to -$1.9584, net income declined 729.38% from $547.6 to -$3.45M, and the quick ratio declined from 2.24 to 1.32.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 11/8/2018 due to a major decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.3051 to -$1.9584, net income declined 729.38% from $547.6 to -$3.45M, and the quick ratio declined from 2.24 to 1.32.
D
Sell
9/7/2018Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from E+ on 9/7/2018 due to a major increase in the growth index, efficiency index and solvency index. Net income increased 119.43% from -$2.82M to $547.6, earnings per share increased from -$4.7535 to $0.3051, and total revenue increased 52.28% from $607.5 to $925.1.
Aytu BioScience, Inc. (AYTU) was upgraded to D from E+ on 9/7/2018 due to a major increase in the growth index, efficiency index and solvency index. Net income increased 119.43% from -$2.82M to $547.6, earnings per share increased from -$4.7535 to $0.3051, and total revenue increased 52.28% from $607.5 to $925.1.
E
Sell
5/15/2018Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to E+ from D- on 5/15/2018 due to a large decline in the growth index, efficiency index and volatility index. Total revenue declined 42.21% from $1.05M to $607.5, EBIT declined 41.93% from -$3.99M to -$5.67M, and operating cash flow declined 31.51% from -$3.1M to -$4.08M.
Aytu BioScience, Inc. (AYTU) was downgraded to E+ from D- on 5/15/2018 due to a large decline in the growth index, efficiency index and volatility index. Total revenue declined 42.21% from $1.05M to $607.5, EBIT declined 41.93% from -$3.99M to -$5.67M, and operating cash flow declined 31.51% from -$3.1M to -$4.08M.
D
Sell
3/1/2018Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 3/1/2018 due to a decline in the volatility index and total return index.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from D on 3/1/2018 due to a decline in the volatility index and total return index.
D
Sell
2/9/2018Upgraded
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 2/9/2018 due to a noticeable increase in the growth index, solvency index and total return index. Earnings per share increased from -$1.7575 to -$0.8929, operating cash flow increased 26.48% from -$4.22M to -$3.1M, and EBIT increased 8.31% from -$4.36M to -$3.99M.
Aytu BioScience, Inc. (AYTU) was upgraded to D from D- on 2/9/2018 due to a noticeable increase in the growth index, solvency index and total return index. Earnings per share increased from -$1.7575 to -$0.8929, operating cash flow increased 26.48% from -$4.22M to -$3.1M, and EBIT increased 8.31% from -$4.36M to -$3.99M.
D
Sell
10/17/2017Downgrade
Aytu BioScience, Inc. (AYTU) was downgraded to D- from C on 10/17/2017 due to a significant decline in the efficiency index, volatility index and total return index. Total capital declined 53.06% from $8.52M to $4M, and net income declined 29.41% from -$5.22M to -$6.75M.
Aytu BioScience, Inc. (AYTU) was downgraded to D- from C on 10/17/2017 due to a significant decline in the efficiency index, volatility index and total return index. Total capital declined 53.06% from $8.52M to $4M, and net income declined 29.41% from -$5.22M to -$6.75M.
C
Hold
3/27/2015Upgraded
Rosewind Corp (RSWN) was upgraded to C from C- on 3/27/2015 due to a large increase in the volatility index and valuation index.
Rosewind Corp (RSWN) was upgraded to C from C- on 3/27/2015 due to a large increase in the volatility index and valuation index.
C
Hold
3/12/2015Downgrade
Rosewind Corp (RSWN) was downgraded to C- from C on 3/12/2015 due to a decline in the volatility index.
Rosewind Corp (RSWN) was downgraded to C- from C on 3/12/2015 due to a decline in the volatility index.
C
Hold
2/13/2015Upgraded
Rosewind Corp (RSWN) was upgraded to C from C- on 2/13/2015 due to a large increase in the volatility index and total return index.
Rosewind Corp (RSWN) was upgraded to C from C- on 2/13/2015 due to a large increase in the volatility index and total return index.
C
Hold
1/13/2015Downgrade
Rosewind Corp (RSWN) was downgraded to C- from C on 1/13/2015 due to a noticeable decline in the growth index and valuation index.
Rosewind Corp (RSWN) was downgraded to C- from C on 1/13/2015 due to a noticeable decline in the growth index and valuation index.
C
Hold
11/26/2014Upgraded
Rosewind Corp (RSWN) was upgraded to C from D+ on 11/26/2014 due to a significant increase in the efficiency index, valuation index and solvency index. Total capital increased 86.67% from -$7.5 to -$14, and debt to equity declined from -0.79 to -0.69.
Rosewind Corp (RSWN) was upgraded to C from D+ on 11/26/2014 due to a significant increase in the efficiency index, valuation index and solvency index. Total capital increased 86.67% from -$7.5 to -$14, and debt to equity declined from -0.79 to -0.69.
D
Sell
7/11/2014Upgraded
Rosewind Corp (RSWN) was upgraded to D+ from D on 7/11/2014 due to a large increase in the growth index, valuation index and solvency index. The quick ratio increased from 0 to 0.18, and operating cash flow increased 73.49% from -$8.3 to -$14.4.
Rosewind Corp (RSWN) was upgraded to D+ from D on 7/11/2014 due to a large increase in the growth index, valuation index and solvency index. The quick ratio increased from 0 to 0.18, and operating cash flow increased 73.49% from -$8.3 to -$14.4.
D
Sell
6/3/2014Downgrade
Rosewind Corp (RSWN) was downgraded to D from D+ on 6/3/2014 due to a significant decline in the volatility index and total return index.
Rosewind Corp (RSWN) was downgraded to D from D+ on 6/3/2014 due to a significant decline in the volatility index and total return index.
D
Sell
4/11/2014Upgraded
Rosewind Corp (RSWN) was upgraded to D+ from D on 4/11/2014 due to an increase in the growth index and valuation index. EBIT increased 37.33% from -$15 to -$20.6, earnings per share increased from -$0.0034 to -$0.0045, and operating cash flow increased 20.29% from -$6.9 to -$8.3.
Rosewind Corp (RSWN) was upgraded to D+ from D on 4/11/2014 due to an increase in the growth index and valuation index. EBIT increased 37.33% from -$15 to -$20.6, earnings per share increased from -$0.0034 to -$0.0045, and operating cash flow increased 20.29% from -$6.9 to -$8.3.
D
Sell
3/6/2014Downgrade
Rosewind Corp (RSWN) was downgraded to D from D+ on 3/6/2014 due to a decline in the total return index.
Rosewind Corp (RSWN) was downgraded to D from D+ on 3/6/2014 due to a decline in the total return index.
NASDAQ
03/12/2025 11:21AM Eastern
Quotes delayed
